Medical articles today

/* 728x15, */

Research Could Lead To Way To Halt Deadly Immune Response

Researchers have teased out the molecular process that can shut down a marauding, often deadly immune response that kills thousands each year who suffer battlefield casualties, heart attacks, strokes, automobile accidents and oxygen deprivation, according to an article published in the January edition of Molecular Immunology. The article provides additional detail about the enormously complex biomechanics of a reaction first observed in the lab by Neel Krishna, Ph.D., and Kenji Cunnion, M.D., while conducting pediatric research at Children's Hospital of The King's Daughters (CHKD) and Eastern Virginia Medical School (EVMS) in Norfolk, Va.

St. Jude Medical Announces European Launch Of USB Cellular Adaptor For Merlin Home Transmitter

St. Jude Medical, Inc. (NYSE:STJ) announced European CE Mark approval of its USB cellular adaptor for the Merlin@home(TM) transmitter, a system that allows important patient data from an implantable cardiac device to be wirelessly downloaded and securely transmitted via telephone for review by a physician. The new USB adaptor allows patients using a Merlin@home transmitter to transfer data to their physician over the cellular network, in addition to the existing landline service previously available. "The USB cellular adaptor allows patients who frequently travel or relocate to be free of the restrictions of a traditional telephone line, " said Dr.

/* 468x60, */

Leading Expert In Hemodynamics Aims To Use New Emulator Technology To Eliminate Blood Clotting In Cardiovascular Devices

On Jan. 22, Danny Bluestein, PhD, Professor of Bioengineering at the State University of New York (SUNY) Stony Brook, in collaboration with Marvin J. Slepian, M.D., Professor of Medicine (Cardiology) at the University of Arizona, submitted a Phase II Quantum Grant proposal to the National Institute of Biomedical Imaging and Bioengineering (NIBIB). "During Phase I of this project, we developed and tested the Device Thrombogenicity Emulator (DTE), " said Dr. Bluestein. "The DTE measures the potential for blood clotting in cardiovascular devices by mimicking the conditions in the device as extracted from advanced numerical simulations. Conceptually, it is analogous to a wind tunnel used for aeronautic and automotive testing.

American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue In Heart Disease Awareness

Racial gaps exist in women's heart-health awareness, women's knowledge of heart attack warning signs requires attention and nearly half of women report they would not call 9-1-1 if they were having heart attack symptoms, according to new research published in Circulation: Cardiovascular Quality and Outcomes, a journal of the American Heart Association. Results of the study, commissioned by the American Heart Association, revealed that although 60 percent of white women were aware of heart disease as the leading cause of death for women, less than half of African-American (43 percent), Hispanic (44 percent) and Asian (34 percent) women identified heart disease as the leading cause.

US FDA Approves New Indication For CRESTOR reg; Rosuvastatin Calcium

AstraZeneca (NYSE: AZN) announced that the US Food and Drug Administration (FDA) has approved CRESTOR® (rosuvastatin calcium) to reduce the risk of stroke, myocardial infarction (heart attack) and arterial revascularization procedures in individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease (CVD) based on age (men 50 and over, women 60 and over), high-sensitivity C-reactive protein (hsCRP) 2 mg/L or more, and the presence of at least one additional CVD risk factor, such as hypertension, low HDL-C, smoking, or a family history of premature coronary heart disease. The FDA approval was based on data from the landmark JUPITER (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin) study which evaluated the impact of CRESTOR 20 mg on reducing major CVD events in a previously unstudied population.

/* 468x60, */

SMT Research And Development, Ltd. Reports Two Successful Clinical Cases

SMT Research and Development, Ltd., a privately held company, announced that it has completed its first two clinical cases using the Shimon Embolic Filter [SHEF] (TM). SMT R&D developed a novel technology for brain protection (Neuroprotection) from stroke complication hazards arising from invasive cardiology procedures and heart surgery. The rate of stroke and silent brain damage is the leading severe limiting factor for delivering the trans-catheter and invasive therapeutic modalities. Neuroprotection from stroke and brain emboli is a largely untapped major field. The SHEF filter reduces significantly the risk of emboli (blood clots and other debris) from traveling to the brain.

Rocket: [100]
/* 160x600, */
Medical articles today © Padayatra Dmitriy
Designer Dimitrov Dmytriy